Clinical trials

A photograph of two women resting their faces close together with eyes closed, sharing a comforting moment
style
background-none
style
background-primary-red

LEARN ABOUT CLINICAL TRIALS

A clinical trial is a research study that tests a medicine or therapy in people to help us understand how well it works and how safe it is.

Clinical trials contribute to the advancement of medicine with the goal of making life better for people. Looking for more details on what to expect from our clinical trials? Find more information here.
Find a clinical trial
style
background-primary-red
additionalPadding
narrow
style
background-primary-red
style
background-none

Learn about
clinical research

style
background-none
additionalPadding
narrow

Clinical trial inclusivity

Including diverse groups of people in any clinical trial is extremely important because people respond differently to medicines depending on their age, sex, race, ethnicity and many other factors. To make sure this trial diversity happens, we work with communities from the start to make our clinical trials as inclusive and accessible as possible for people around the world.

Learn about our commitment to diversity in clinical trials here.
style
background-none, two-col-25-75
extra-styles
offset
style
background-none

Clinical trial participants

We can’t conduct trials without help from clinical trial participants. Every clinical trial participant provides valuable information to advance medical research and helps move medicines forward to reach countless people waiting for them.
extra-styles
offset
style
two-col-25-75
style
background-none
A photograph of two healthcare workers in scrubs walking side by side down a sunlit corridor

Independent clinical research

In addition to sponsoring our own clinical research and research collaborations, we also have programs that allow us to support external requests. We can provide resources and/or financial support for independent clinical research that is initiated, designed and sponsored by external researchers.

We consider independent clinical research projects based on scientific merit and strategic fit with our areas of research interest. These reviews are carried out by global committees composed of Lilly medical and scientific staff members from relevant therapeutic areas. For any inquiries, please reach out to your Lilly medical representative

Health care and research professionals may submit a concept online.
Submit a concept now
style
background-primary-red
additionalPadding
narrow
style
background-none

Thank you, clinical
trial participants

Clinical trial participants help pave the way for new, groundbreaking medical treatments. We're grateful to every participant who help us advance science.
style
background-none, two-col-75-25
extra-styles
offset
style
background-none
additionalPadding
narrow
Microscope icon
style
background-none, two-col-25-75
extra-styles
offset

Clinical trials transparency

We have a history of transparency when it comes to our clinical studies. In 2004, we became the first company to voluntarily disclose our clinical studies initiation and post-study results in a publicly available registry.

Since the start of 2014, we have enhanced our transparency initiatives to align with the PhRMA/EFPIA Principles for Responsible Clinical Trial Data Sharing. We recognize that sharing clinical study data can enhance public health. But responsibly sharing that data is necessary to safeguard the privacy of patients, respect the integrity of national regulatory systems, and maintain incentives for investments in biomedical research.
style
background-none, two-col-25-75
extra-styles
offset

Clinical Trial Registration

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px

Lilly currently registers all Lilly-sponsored interventional clinical trials on clinicaltrials.gov and, in many cases, on other online registries. Lilly-sponsored studies are registered as follows:

  • Phase 2, phase 3 and phase 4 clinical trials initiated on or after October 15, 2002
  • Phase 1 clinical trials in patients initiated on or after October 1, 2009
  • Phase 1 clinical trials in healthy subjects initiated on or after October 1, 2010

Clinical studies of Lilly products may also be sponsored and reported by parties other than Lilly in other clinical trial registries.

Lilly currently registers all Lilly-sponsored interventional clinical trials on clinicaltrials.gov and, in many cases, on other online registries. Lilly-sponsored studies are registered as follows:

  • Phase 2, phase 3 and phase 4 clinical trials initiated on or after October 15, 2002
  • Phase 1 clinical trials in patients initiated on or after October 1, 2009
  • Phase 1 clinical trials in healthy subjects initiated on or after October 1, 2010

Clinical studies of Lilly products may also be sponsored and reported by parties other than Lilly in other clinical trial registries.

Clinical Trial Results

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px

Lilly posts results of all registered Lilly-sponsored clinical trials.

Since September 27, 2007, results of Lilly clinical trials have been presented on clinicaltrials.gov for compounds that are approved for use in humans. Since January 2019, results of all Lilly-registered clinical trials are provided on clinicaltrials.gov either 30 days after the approval of the medicine (Phase 1) or within one year after a trial has completed (Phases 2-4).

For medicines approved and trials completed prior to December 8, 2007, Phases 2-4 clinical trial results are presented in a Clinical Study Report (CSR) Synopsis format on this website's CSR Synopsis page.

Lilly also provides results of the registered Lilly-sponsored clinical trials for compounds whose development has been terminated on or after October 1, 2009.

Lilly posts results of all registered Lilly-sponsored clinical trials.

Since September 27, 2007, results of Lilly clinical trials have been presented on clinicaltrials.gov for compounds that are approved for use in humans. Since January 2019, results of all Lilly-registered clinical trials are provided on clinicaltrials.gov either 30 days after the approval of the medicine (Phase 1) or within one year after a trial has completed (Phases 2-4).

For medicines approved and trials completed prior to December 8, 2007, Phases 2-4 clinical trial results are presented in a Clinical Study Report (CSR) Synopsis format on this website's CSR Synopsis page.

Lilly also provides results of the registered Lilly-sponsored clinical trials for compounds whose development has been terminated on or after October 1, 2009.

Observational Studies Registration and Results

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px

Lilly posts information on observational (or non-interventional) Lilly-sponsored studies that started on or after September 1, 2007.

The studies posted are those where a Lilly marketed product is evaluated in comparison to alternative treatment(s) or control group(s), using pre-defined hypotheses/endpoints. These include the following:

Lilly posts information on observational (or non-interventional) Lilly-sponsored studies that started on or after September 1, 2007.

The studies posted are those where a Lilly marketed product is evaluated in comparison to alternative treatment(s) or control group(s), using pre-defined hypotheses/endpoints. These include the following:

Studies with primary patient-level data collection:

  • Prospective effectiveness studies evaluating the extent to which treatment with a Lilly marketed product improves patient outcomes compared to the alternative treatments in actual clinical practice.
  • Prospective pharmacoepidemiologic studies, i.e., studies that are designed to assess the risk attributed to a drug exposure.

Studies utilizing secondary data sources or databases with safety as the primary endpoint:

  • Retrospective pharmacoepidemiologic studies, i.e., studies that are designed to assess the risk attributed to a drug exposure.

Lilly observational studies may be registered at the following locations:

Clinical Study Data-Sharing

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px
  • Prospective effectiveness studies evaluating the extent to which treatment with a Lilly marketed product improves patient outcomes compared to the alternative treatments in actual clinical practice.
  • Prospective pharmacoepidemiologic studies, i.e., studies that are designed to assess the risk attributed to a drug exposure.
Lilly makes patient-level data available from Lilly-sponsored studies on marketed drugs for approved uses following acceptance for publication. Lilly provides this access through the Vivli Center for Global Clinical Research Data website. Qualified researchers can submit research proposals and request anonymized data to test new hypotheses. Lilly’s data-sharing policies are provided on Vivli’s Members page.

For further information on the process for requesting data from Lilly studies, see the step-by-step process here.

Sharing Results With Patients

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px
  • Retrospective pharmacoepidemiologic studies, i.e., studies that are designed to assess the risk attributed to a drug exposure.
Lilly creates summaries of Phase 2 and 3 clinical trial results written in patient-friendly language using simple, everyday terms. These lay summaries are available to the study investigators to provide to study participants.

Publication Policy

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-2column, column1-contenttypenone, column2-seccontenttypedescription, seccontentdescription-fs-16px
Initially, observational studies that were started on or after September 1, 2007 are located at clinicaltrials.gov or Lilly’s clinical study report synopses site.

Starting in 2014, Lilly started registering and posting results to observational/non-interventional studies on the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP®).
Since 2003, Lilly’s public policy on disclosure of clinical trial data has guided us to disclose publicly all medical research results that are significant to patients, health care providers or payers – whether favorable or unfavorable to a Lilly product – in an accurate, objective and balanced manner for customers to make more informed decisions about Lilly products.

As part of the Principles for Responsible Clinical Trial Data Sharing, Lilly reaffirms our commitment to consider for publication all company-sponsored clinical trials in the scientific literature, regardless of whether the results of the sponsors’ clinical trials are positive or negative. At a minimum, results should be submitted for publication in a peer-reviewed journal for all Phase 3 clinical trials (by 18 months after last patient visit) and for any clinical trial results of significant medical importance. This commitment also pertains to investigational medicines whose development programs have been discontinued.
style
background-none
additionalPadding
narrow

Find a clinical trial near you

Find a trial
style
background-primary-red
additionalPadding
narrow
additionalMargin
narrow
roundedBorders
true
PP-LLY-CA-0032 04/2026 © 2026, Eli Lilly and Company. All rights reserved.
style
background-none
additionalPadding
narrow